Streetbeat News

NYXH

Nyxoah S.A.

https://www.nyxoah.com

Industry

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Open

9.45

Mkt cap

326M

Volume

48K

High

9.58

P/E Ratio

-5.13

52-wk high

20.00

Low

9.01

Div yield

N/A

52-wk low

4.00

HC Wainwright & Co. has maintained a Buy rating on Nyxoah (NASDAQ:NYXH) but lowered the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 7:13 pm

Tesla's shares fell 5.6% in pre-market trading after a disappointing robotaxi unveiling event. Other stocks like A. O. Smith, Lilium, and Indivior also saw declines due to various reasons including lowered earnings forecasts and revenue guidance.

Portfolio Pulse from Avi Kapoor

October 11, 2024 | 12:40 pm

Nyxoah SA announced that BlackRock, Inc. holds a 3.25% stake in the company, consisting of 1,032,521 shares and 83,900 financial instruments, following a change in BlackRock's group structure.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 8:32 pm

Nyxoah has raised $27 million through an at-the-market offering by selling 3 million shares. This move is likely to impact the company's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 9:05 pm

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Nyxoah (NASDAQ:NYXH) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 10:30 am

Nyxoah presented data from its DREAM pivotal study at the International Surgical Sleep Society 2024, showing a 71% median reduction in Apnea-Hypopnea Index for patients with Obstructive Sleep Apnea. The study also reported significant improvements in quality-of-life outcomes.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 8:32 pm

Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on Nyxoah (NASDAQ:NYXH) but lowers the price target from $17 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 5:58 pm

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Nyxoah (NASDAQ:NYXH) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 12:24 pm

Oppenheimer analyst Suraj Kalia maintains an Outperform rating on Nyxoah (NASDAQ:NYXH) but lowers the price target from $15 to $13.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:58 am

Nyxoah (NASDAQ:NYXH) reported Q2 2024 GAAP EPS of $(0.46), missing the $(0.40) estimate by 15%. Sales were $830.066K, missing the $1.798M estimate by 53.83% and down 31.23% from last year's $1.207M.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 8:54 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.